Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum
Executive Summary
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
You may also be interested in...
Biohaven Gets Pfizer’s Help To Make Nurtec An Ex-US Success Story Too
As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.
Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.
Keeping Track: US FDA Approves Amgen’s Lumakras, Myovant’s Myfembree; New Claims For Biohaven’s Nurtec, BMS’ Zeposia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker